

NOTICE

Notice is hereby given Pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of Board of Directors of the Company will be held on Monday, 29th May, 2019 at 11:00 A.M. at its Registered Office at Room No. 1, 2nd Floor, 62A, Dr. Meghnad Shah Sarani, Southern Avenue, Kolkata - 700 029, to consider and adopt the Audited Financial Results for the 04th quarter and year ended 31st March, 2019, and other matters as per agenda.

Further, the trading window under SEBI (Prohibition of Insider Trading) Regulations, 2015 read with Code of Conduct framed by the Company has been already closed for all designated persons of the Company and their relatives and shall remain closed till the 48 hours end after the results made public.

The intimation is also available on the website of the Company (www.lkhamiconsulting.com) and Stock Exchanges website (www.bseindia.com) and (www.cse-india.com) for further details.

By order of the Board
For Lkhami Consulting Limited
Pradip Kumar Ghosh

Place: Kolkata Whole Time Director
Date: 08.05.2019 DIN: 07799909

ADINATH BIO-LABS LIMITED

CIN: L24230WB1982PLC034492
Regd. Office: 4, Netaji Subhas Road,
1st Floor, Kolkata - 700 001
Email: investors@adinathbio.com,
Website: www.adinathbio.com

NOTICE

Notice is hereby given Pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, that a Meeting of Board of Directors of the Company will be held on Wednesday, 29th May, 2019 at 11:30 A.M. at its Registered Office at 4, N. S. Road, 1st Floor, Kolkata - 700 001, to consider and adopt the Audited Financial Results for the quarter and year ended 31st March, 2019 and other matters as per agenda.

Further, the trading window under SEBI (Prohibition of Insider Trading) Regulations, 2015 read with Code of Conduct framed by the Company has been already closed for all designated persons of the Company and their relatives and shall remain closed till the 48 hours end after the results made public.

The intimation is also available on the website of the Company (www.adinathbio.com) and Stock Exchange website (www.cse-india.com) for further details.

By order of the Board
For Adinath Bio-Labs Limited
Kishan Singh

Place: Kolkata (Whole-Time Director)
Date: 08.05.2019 DIN: 07526266

MAVENS BIOTECH LIMITED

FRIDAY, MAY 3, 2019

ASBA*

Simple, Safe, Smart way of making an application - Make use of it !!!

*Applicator ASBA below

Please note that in accordance with Regulation 76 of the SEBI ICDR Regulations read with the provisions of the SEBI circular CIR/Investors complying with the eligibility conditions under Regulation 76 of the SEBI ICDR Regulations must mandatorily invest in the conditions have the option to apply through the ASBA process or the non-ASBA process. Eligible Equity Shareholders who have ren Rights Equity Shares only through the non-ASBA process, irrespective of the Application amounts/ Applicant category. ASBA Investors read the provisions applicable to such applications before making their application through the ASBA process. For details, see the Abridged Prospectus dated January 2, 2013, it is clarified that for making applications by SCSBs on own account using ASBA facility, SCSBs should have a s APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA): Investors may apply through the ASBA process subject to the cor block the amount in the ASBA account as per the authority contained in the CAF and undertake other tasks as per the specified proc Registrar, our Company and the Lead Managers, to the respective SCSB. For details on the ASBA process, please refer to the detail banks which have been notified by SEBI to act as SCSBs for the ASBA process is provided on [NON-ASBA APPLICATIONS: In case of non-ASBA application, the CAF duly completed together with the amount payable on applic banking hours on or before the Issue Closing Date, i.e., Friday, May 17, 2019. Separate cheque/demand draft must accompany each Resident Investors residing at places other than the places where the collection centres have been opened by our Company should postal charges drawn in favour of "BHARTI AIRTEL - RIGHTS ISSUE - ESCROW COLLECTION - R" crossed "A/c Payee only" and pay centres have been opened by our Company are requested to send their CAFs together with demand draft payable at Hyderabad for tr at par, in case of non-resident Investors applying on repatriation basis and in favour of "BHARTI AIRTEL - RIGHTS ISSUE - ESCRC to reach them on or before the Issue Closing Date, i.e., Friday, May 17, 2019. Such application sent to anyone other than Registrar or su](http://www.sebi.gov.in/sebiweb/other/O ELIGIBLE EQUITY SHAREHOLDERS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE ALLOTTED ONLY IN DE SINCE ALLOTMENT IN THIS ISSUE WILL OCCUR SUBSEQUENT TO MAY 10, 2019, THE ENTITLEMENT OF RIGHTS EQUITY ABEYANCE IN ELECTRONIC MODE BY OUR COMPANY UNTIL THE APPLICANTS PROVIDE DETAILS OF THEIR DEMAT ACC DISPATCH OF ALOF AND CAF: The dispatch of ALOF along with CAF for the Issue has been completed by Registrar to the Issu names appeared in the Register of Members/Beneficial Owners of our Company, on the Record Date, i.e., Wednesday, April 24, 2019.</p>
</div>
<div data-bbox=)

AVAILABILITY OF DUPLICATE CAF: In case the original CAF is not received, or is misplaced by the Eligible Equity Shareholder, t address to the Registrar. However, if the Registrar receives any request for issue of duplicate CAF from Eligible Equity Shareholder such Eligible Equity Shareholders. Please note that the request for duplicate CAF should reach the Registrar at least seven days pr even if it is received or found, as the case may be, subsequently. If the Investor violates such requirements, he/ she shall face the risk APPLICATION ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder who has neither received the origina Eligible Equity Shareholders should submit the same with the SCSB. Applications on plain paper will not be accepted from any addre The envelope should be superscribed "Bharti Airtel Limited - Rights Issue" and should be postmarked in India. The Application on pl the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

1. Name of the Company, being Bharti Airtel Limited; 2. Name and address of the Eligible Equity Shareholder including joint holders Rights Equity Shares entitled to; 7. Number of Rights Equity Shares applied for within the Rights Entitlement; 8. Number of additior ASBA Account such as the account number, name, address and branch of the relevant SCSB; 12. In case of NR Eligible Equity Share Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each t the SCSB to block an amount equivalent to the Application Money in the ASBA Account; 15. Signature of the Applicant (in case o Application will result in increase in shareholding of the Applicant in excess of 5% of the post-Issue paid-up Equity Share capital of o The list of banks which have been notified by SEBI to act as SCSBs for the ASBA process are provided at

1. Name of the Company, being Bharti Airtel Limited; 2. Name and address of the Eligible Equity Shareholder including joint holde held in physical form; 6. Allotment option preferred - physical or dematerialised form; 7. Number of Rights Equity Shares entitled to; 1 applied for; 11. Total amount paid at the rate of ₹ 220 per Rights Equity Share; 12. Particulars of cheque/demand draft; 13. Sa dematerialized form, the Registrar shall obtain the bank account details from the information available with the Depositories; 14. E each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Rights Equity Shares applied for pursu confirming that the draft has been issued by debiting the NRE or FCNR or NRO Account; 16. Signature of the Applicant (in case Application will result in increase in shareholding of the Applicant in excess of 5% of the post-Issue paid-up Equity Share capital of c

Please note that Eligible Equity Shareholders who are making the application otherwise than on CAF shall not be entitled to renou violates such requirements, he/ she shall face the risk of rejection of both the applications. Our Company shall refund such applic multiple CAFs are submitted, including cases where an investor submits CAFs along with a plain paper application, such applica Lead Manager and the Registrar not having any liability to the Investor. The plain paper application format will be available on the w OVERSEAS SHAREHOLDERS: The distribution of the LOF, ALOF or CAFs or any other offering material and the issue of Rights Equ or any other offering material may come are required to inform themselves about and observe such restrictions. Our Company is mak shareholders who do not update our Company with their Indian address or the address of their duly authorized representative in India jurisdiction where action would be required for that purpose. Accordingly, the Rights Entitlement or Rights Equity Shares may not be of For further details, see section "Notice to Overseas Investors" on page 8 of the LOF.

The LOF, ALOF and CAF shall be dispatched to non-resident Eligible Equity Shareholders at their Indian address only as NO OFFER IN THE UNITED STATES

The Rights Entitlements and the Rights Equity Shares have not been and will not be registered under the United States Securities transaction exempt from the registration requirements of the US Securities Act. The Rights Entitlements and Rights Equity Shares united states to "Qualified Institutional Buyers" (as defined in rule 144A under the US Securities Act) ("QIBs") in transactions exempt Rights Equity Shares or Rights Entitlements for sale in the United States or as a solicitation therein of an offer to buy any of the said Neither our Company, nor any person acting on behalf of our Company, will accept a subscription or renunciation from any person made (other than persons in the United States who are QIBs). Envelopes containing a CAF should not be postmarked in the U Any person who acquires Rights Entitlements or Rights Equity Shares will be deemed to have declared, warranted and agreed, b